There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Supernus Pharmaceuticals (SUPN) and Biolinerx (BLRX) with bullish sentiments.
Supernus Pharmaceuticals (SUPN)
Mizuho Securities analyst Irina Rivkind Koffler maintained a Buy rating on Supernus Pharmaceuticals yesterday and set a price target of $59. The company’s shares closed yesterday at $33.30, close to its 52-week low of $29.60.
According to TipRanks.com, Koffler ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.8% and a 33.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Supernus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $59.50.
See today’s analyst top recommended stocks >>
Biolinerx (BLRX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx today and set a price target of $18. The company’s shares closed yesterday at $3.46, close to its 52-week low of $3.32.
Pantginis observed:
“Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $18 from $3, based on the following factors: (1) adjustment to base year; (2) adjustment ot fully diluted share count; (3) accounting for the 1 for 15 reverse split; and (4) increasing our discount rate to 30% from our usual 15%, to account for increased perceived risk in developing drugs for both pancreatic cancer and AML. We note that there is still a relatively large delta between the current share price and our target, which is now also largely attributable to the low number of shares outstanding post-reverse split.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -12.8% and a 27.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Currently, the analyst consensus on Biolinerx is a Moderate Buy with an average price target of $27.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
